When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ENTA - Enanta's oral drug EDP-235 for COVID-19 gets FDA fast track status
Enanta Pharmaceuticals Inc.
The U.S. Food and Drug Administration (FDA) granted fast track designation to Enanta Pharmaceuticals' (NASDAQ:ENTA) oral drug EDP-235 for preventing and treating COVID-19. Currently EDP-235 is being evaluated in a phase 1 study. “We believe that the profile of EDP-235 positions it as a potential best-in-class antiviral therapeutic and we remain on track to report data from our ongoing Phase 1 study of EDP-235 next quarter," said Enanta President and CEO Jay Luly.